Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

Recruiting now

Conditions studied: Hepatocellular Carcinoma (HCC)

In brief

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Key facts

Study ID

NCT07303712

Run by

Palo Alto Veterans Institute for Research

People needed

12

Starts

2024-08-01

Expected to finish

2026-12-01

Last updated by the study team

2025-12-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > or = 18 years
• HCC confirmed on imaging, BCLC stage 0, A, B, or C
• Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

You may not qualify if…

• Not eligible for Y90 procedure
• Prior surgery or ablation on indicated tumors
• Patient unable to complete the follow up visits required for clinical care or research -

Where it is running

• VA Palo Alto Health Care System — Palo Alto, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.